Does the risk of electronic cigarettes exceed potential benefits? No

Chest

Volumn 148, Issue 3, 2015, Pages 582-584

  Middlekauff, Holly R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINE; PROPYLENE GLYCOL;

CANCER RISK; CAUSE OF DEATH; EDITORIAL; ELECTRONIC CIGARETTE; HUMAN; NICOTINE REPLACEMENT THERAPY; NONHUMAN; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SMOKING CESSATION; SMOKING REGULATION; ADVERSE EFFECTS; HARM REDUCTION; PROCEDURES; RISK; SAFETY; TOBACCO USE DISORDER; UNITED STATES;

ELECTRONIC CIGARETTES; HARM REDUCTION; HUMANS; NICOTINE; RISK; SAFETY; SMOKING CESSATION; TOBACCO USE DISORDER; UNITED STATES;

EID: 84941711201     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.15-0540     Document Type: Editorial

References (26)

1. Cobb NK, Abrams DB. The FDA, e-cigarettes, and the demise of combusted tobacco. N Engl J Med. 2014; 371 ( 16): 1469-1471.
2. Kaur J, Rinkoo AV. A call for an urgent ban on E-cigarettes in India-A race against time. Global Health Promotion. 2015; 22 ( 2): 71-74.
3. Steinberg MB, Zimmermann MH, Delnevo CD, et al. E-cigarette versus nicotine inhaler: comparing the perceptions and experiences of inhaled nicotine devices. J Gen Intern Med. 2014; 29 ( 11): 1444-1450.
4. Brook RD, Rajagopalan S, Pope CA III, et al; American Heart Association Council on Epidemiology and Prevention, Council on the Kidney in Cardiovascular Disease, and Council on Nutrition, Physical Activity and Metabolism. Particulate matter air pollution and cardiovascular disease: An update to the scientifi c statement from the American Heart Association. Circulation. 2010; 121 ( 21): 2331-2378.
5. Goniewicz ML, Knysak J, Gawron M, et al. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tob Control. 2014; 23 ( 2): 133-139.
6. Cahn Z, Siegel M. Electronic cigarettes as a harm reduction strategy for tobacco control: A step forward or a repeat of past mistakes? J Public Health Policy. 2011; 32 ( 1): 16-31.
7. Wang T, Noonberg S, Steigerwalt R, et al. Preclinical safety evaluation of inhaled cyclosporine in propylene glycol. J Aerosol Med. 2007; 20 ( 4): 417-428.
8. Woolf KJ, Zabad MN, Post JM, McNitt S, Williams GC, Bisognano JD. Eff ect of nicotine replacement therapy on cardiovascular outcomes aft er acute coronary syndromes. Am J Cardiol. 2012; 110 ( 7): 968-970.
9. Greenland S, Satterfi eld MH, Lanes SF. A meta-analysis to assess the incidence of adverse effects associated with the transdermal nicotine patch. Drug Saf. 1998; 18 ( 4): 297-308.
10. Benowitz NL, Gourlay SG. Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J Am Coll Cardiol. 1997; 29 ( 7): 1422-1431.
11. Murray RP, Bailey WC, Daniels K, et al; Lung Health Study Research Group. Safety of nicotine polacrilex gum used by 3, 094 participants in the Lung Health Study. Chest. 1996; 109 ( 2): 438-445.
12. Etter JF, Stapleton JA. Nicotine replacement therapy for long-term smoking cessation: A meta-analysis. Tob Control. 2006; 15 ( 4): 280-285.
13. Farsalinos KE, Spyrou A, Tsimopoulou K, Stefopoulos C, Romagna G, Voudris V. Nicotine absorption from electronic cigarette use: comparison between fi rst and new-generation devices. Sci Rep. 2014; 4 : 4133.
14. Bullen C, McRobbie H, Thornley S, Glover M, Lin R, Laugesen M. Eff ect of an electronic nicotine delivery device (e cigarette) on desire to smoke and withdrawal, user preferences and nicotine delivery: randomised cross-over trial. Tob Control. 2010; 19 ( 2): 98-103.
15. Dawkins L, Turner J, Hasna S, Soar K. The electronic-cigarette: effects on desire to smoke, withdrawal symptoms and cognition. Addict Behav. 2012; 37 ( 8): 970-973.
16. Bullen C, Howe C, Laugesen M, et al. Electronic cigarettes for smoking cessation: A randomised controlled trial. Lancet. 2013; 382 ( 9905): 1629-1637.
17. Caponnetto P, Campagna D, Cibella F, et al. Effi Ciency and safety of an eLectronic cigAreTte (ECLAT) as tobacco cigarettes substitute: A prospective 12-month randomized control design study. PLoS ONE. 2013; 8 ( 6): e66317.
18. Godtfredsen NS, Vestbo J, Osler M, Prescott E. Risk of hospital admission for COPD following smoking cessation and reduction: A Danish population study. Thorax. 2002; 57 ( 11): 967-972.
19. Godtfredsen NS, Holst C, Prescott E, Vestbo J, Osler M. Smoking reduction, smoking cessation, and mortality: A 16-year follow-up of 19, 732 men and women from The Copenhagen Centre for Prospective Population Studies. Am J Epidemiol. 2002; 156 ( 11): 994-1001.
20. Pope CA III, Burnett RT, Krewski D, et al. Cardiovascular mortality and exposure to airborne fine particulate matter and cigarette smoke: shape of the exposure-response relationship. Circulation. 2009; 120 ( 11): 941-948.
21. Pope CA I II, Burnett RT, Turner MC, et al. Lung cancer and cardiovascular disease mortality associated with ambient air pollution and cigarette smoke: shape of the exposure-response relationships. Environ Health Perspect. 2011; 119 ( 11): 1616-1621.
22. Warner KE. An endgame for tobacco? Tob Control. 2013; 22( suppl 1): i3-i5.
23. Kandel ER, Kandel DB. Shattuck lecture. A molecular basis for nicotine as a gateway drug. N Engl J Med. 2014; 371 ( 10): 932-943.
24. Polosa R, Caponnetto P. Time for evidence-based e-cigarette regulation. Lancet Oncol. 2013; 14 ( 13): e582-e583.
25. Arrazola RA, Neff LJ, Kennedy SM, Holder-Hayes E, Jones CD; Centers for Disease Control and Prevention (CDC). Tobacco use among middle and high school students-United States, 2013. MMWR Morb Mortal Wkly Rep. 2014; 63 ( 45): 1021-1026.
26. Dwyer JB, McQuown SC, Leslie FM. The dynamic effects of nicotine on the developing brain. Pharmacol Ther. 2009; 122 ( 2): 125-139.